Evaluation of a replication-competent VSV-SIV vaccine candidate by Jurgens CK, Morrow G, Boggiano C, Panis M, Coleman J, Powell R, Yuan M, Kemelman M, Tamot N, Lopez M, Ouattara A, Iyer S, Backer M, Wright K, Domi A, Chiuchiolo M, King CR, Caulfield M, Parks C

Viral vector delivery of Env trimer immunogens by Parks CL, Rabinovich S, Tiberio PJ, Wright KJ, Yuan M, Delboy MG, Kemelman M, Wilson AJ, Powell RL, Hoffenberg S, Chiuchiolo MJ, Boggiano C, Morrow G, Lorenz IC, Jurgens CK, Zhang X, Lindsay RW, Koff WC, King CR, Caulfield MJ

Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies by King, LDW, Pulido, D, Barrett, JR, Davies, H, Quinkert, D, Lias, AM, Silk, SE, Pattinson, DJ, Diouf, A, Williams, BG, McHugh, K, Rodrigues, A, Rigby, CA, Strazza, V, Suurbaar, J, Rees-Spear, C, Dabbs, RA, Ishizuka, AS, Zhou, Y, Gupta, G, Jin, J, Li, Y, Carnrot, C, Minassian, AM, Campeotto, I, Fleishman, SJ, Noe, AR, MacGill, RS, King, CR, Birkett, AJ, Soisson, LA, Long, CA, Miura, K, Ashfield, R, Skinner, K, Howarth, MR, Biswas, S, Draper, SJ

Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype by Barrett, JR, Pipini, D, Wright, ND, Cooper, AJR, Gorini, G, Quinkert, D, Lias, AM, Davies, H, Rigby, CA, Aleshnick, M, Williams, BG, Bradshaw, WJ, Paterson, NG, Martinson, T, Kirtley, P, Picard, L, Wiggins, CD, Donnellan, FR, King, LDW, Wang, LT, Popplewell, JF, Silk, SE, de Ruiter Swain, J, Skinner, K, Kotraiah, V, Noe, AR, MacGill, RS, King, CR, Birkett, AJ, Soisson, LA, Minassian, AM, Lauffenburger, DA, Miura, K, Long, CA, Wilder, BK, Koekemoer, L, Tan, J, Nielsen, CM, McHugh, K, Draper, SJ